Biohealth Innovation
As Maryland emerges as a hotbed for research and commercial opportunities in the biohealth industry, many small businesses in this sector see the state as a good place to grow. When William Hearl started building Rockville-based Immunomic Therapeutics Inc. a decade ago, much of the initial learning curve was finding that sweet spot between creating their
So you want to work for a biotech startup. Why not? It seems like a glamour job, working on the very bleeding edge of science. And admit it—in the back of your mind, you’re thinking it’ll become the next Genentech (RHHBY) and you’ll be rich with all your stock options.
TEDCO’s Entrepreneur Expo came to Baltimore this year, hosting an all-day session at the Hilton on Monday.
The annual event attracts founders, investors and other community members from around the state. For the past several years, it was held in Columbia.
Startup Maryland yesterday unveiled the finalist for the Pitch Across Maryland Competition. Startup Maryland is proud to showcase the finalists along with all the ventures who participated in the 2016 STRT1UP Roadshow celebration of innovation and entrepreneurship. This year's Finalist for each category are listed below with a link to their 2016 pitch video:
Faculty from the University of Maryland, Baltimore and Johns Hopkins University and local entrepreneurs were recently recognized for their groundbreaking research with $200,000 in prizes.
The awards were made by the two universities, the Abell Foundation and the Maryland Department of Commerce as part of a day-long 2016 Innovation Showcase. The event was cohosted by the Johns Hopkins Alliance for Science and Technology Development and the University of Maryland, Baltimore Commercial Advisory Board.
Baltimore-based Glyscend Inc. was awarded one of three $500,000 research grants from Johnson & Johnson Innovation LLC and its research arm Janssen as part of the health care giant's World Without Disease QuickFire Challenge.
Glyscend was spun out of Johns Hopkins University and continues operations as part of the Johns Hopkins Technology Ventures program. The company is currently in the process of raising a Series A funding round, with a goal of between $5 million and $10 million. The Johnson & Johnson (NYSE: JNJ) grant money will help the company reach its goal, said Ashish Nimgaonkar, co-founder and CEO.
HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) and QIAGEN Manchester Limited, a wholly owned subsidiary of QIAGEN N.V. (Nasdaq: QGEN). This Agreement creates a framework for both companies to combine their technological and commercial strengths with the goal to offer pharmaceutical companies a complete NGS-based solution for the development and commercialization of companion diagnostics, with a focus in oncology. Together with the parties’ entry into the Agreement, QIAGEN North American Holdings, Inc., another QIAGEN subsidiary, made a minority investment in HTG’s common stock.
Deloitte today released the 2016 Technology Fast 500, an annual ranking of the fastest growing North American companies in the technology, media, telecommunications, life sciences and energy tech sectors. Loot Crate claimed the top spot with a growth rate of 66,661 percent from 2012 to 2015.
Based in Los Angeles, Loot Crate delivers monthly curated mystery boxes of entertainment and pop culture themed collectibles to fans. Founded in 2012, Loot Crate has more than 650,000 subscribers worldwide in 35 countries. Loot Crate's position at the top of this year's list showcases how innovation isn't always about new technology and invention, but also about ingenuity, the recombining of existing assets and know-how in new ways to maximize value.
AstraZeneca today announced the completion of the licensing agreement between MedImmune, its global biologics research and development arm, and Allergan plc, for the global rights to MEDI2070.
MEDI2070 is an IL-23 monoclonal antibody currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease and ready for Phase II for ulcerative colitis, diseases that sit outside AstraZeneca’s three main therapy areas.
Calling all innovators, startups, and entrepreneurs: join us in participating in the first-ever #FosterlyCensus -- a region-wide, community project gathering information and statistics about our rapidly expanding ecosystem. Be a part of the most comprehensive, resourceful survey our city has ever seen by filling out the info at http://fosterly.com.
California, the nation’s birthplace of biotechnology, continues to add jobs in that sector and the life sciences in general, a trade association reported Wednesday.
While growth is slow, the life sciences remain a potent economic force, especially in San Diego County and the San Francisco Bay area. There are also signs of expansion in Los Angeles County, which has long been overshadowed by its neighbors to the north and south.
International Trade - The Basics for Bio & Technology Companies
Attend this lunch-and-learn event to hear global industry experts discuss how Maryland companies can leverage resources to fund and market their international ambitions. Hear from one local company who has successfully taken advantage of these tools. WHO SHOULD ATTEND: Existing companies and startups in the life sciences and health technology industries
Integrated BioTherapeutics (IBT) announced today that it has entered into an exclusive worldwide license agreement with Emergent BioSolutions Inc. (NYSE: EBS) whereby Emergent will gain exclusive rights to use IBT's proprietary vaccine antigens and know-how in a joint research, development, and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses. Financial terms of the agreement are not disclosed.
OCTOBER 27, 2015 @ 8:00 AM - OCTOBER 29, 2015 @ 5:00 PM
Join us for the 17th Annual National Institutes of Health Small Business Innovation Research & Small Business Technology Transfer Conference. This year’s conference From Washington to Washington: Supporting Small Business Innovation for Health, will provide attendees an opportunity to learn more about the $780 million in annual NIH funding available exclusively for small businesses to perform innovative research and build new businesses based on their technologies.
A Chinese group has become the first to inject a person with cells that contain genes edited using the revolutionary CRISPR–Cas9 technique.
On 28 October, a team led by oncologist Lu You at Sichuan University in Chengdu delivered the modified cells into a patient with aggressive lung cancer as part of a clinical trial at the West China Hospital, also in Chengdu.
As the IoT reels from and struggles with ongoing security issues stemming from DDoS and botnet and SSH and DNS and innumerable other interrelated problems, the industry needs outside input and leadership to give it strategic guidance.
According to a recent announcement, one such source of guidance will be in the form of the Rockville Innovation Center (RIC) in Montgomery County, Maryland, where BioHealth Innovation (BHI) has partnered with The MITRE Corporation, a not-for-profit corporation that operates federally funded research and development centers (FFRDCs), including the National Cybersecurity FFRDC, to look for innovative solutions to next-generation security threats.
A $25,000 contribution from AT&T will help the MdBio Foundation boost science, technology, engineering and math (STEM) education in Maryland. The contribution supports MdBio programs for underserved high school and rising middle school students, including the MdBioLab, a mobile laboratory that travels across the state giving students hands-on STEM experiences.
Brian Gaines, CEO of the MdBio Foundation, made the announcement during today’s Advancing Tomorrow’s Leaders in STEM (ATLAS) event at the University of Maryland BioPark in Baltimore. ATLAS is a college and career readiness symposium that offers students underrepresented in STEM an opportunity to connect with business leaders, colleges, government agencies and potential employers.
Roche has launched a global cancer immunotherapy Centers of Research Excellence network, saying it will invest up to 100 million Swiss francs ($100.3 million) in the project.
The research network of 21 academic centers around the world is intended to support basic and clinical research collaboration to advance the science of cancer immunotherapy, the Basel-based drugmaker said on Tuesday.
Emergent BioSolutions (EBS -1.9%) and Integrated BioTherapeutics enter into a joint research, development and manufacturing collaboration focused on an equine-based hyperimmunoglobulin for the treatment of hemorrhagic fever caused by Filoviruses. Under the partnership, Integrated Bio extends an exclusive global license to its proprietary vaccine antigens and know-how to EBS. Financial terms are not disclosed.
Learn what the corporates are thinking.
This webinar series highlights the technical and scouting needs of our Corporate Selection Committee for the University Startups Conference and Demo Day. Each session will feature speakers from open innovation, corporate venture, and R&D to talk about what they are looking for from universities and startups, and partners in the investment community.
Gaitherburg-based OpGen Inc. has entered a new partnership with pharmaceutical giant Merck & Co. in a collaboration officials say will help more quickly combat so-called superbugs with rapid diagnostic tests.
OpGen, which has focused on creating rapid DNA diagnostic tools to improve antibiotic decision-making, has been building a bank of bacterial pathogens to offer more accurate infection diagnostic testing.
The Tech Council of Maryland is pleased to announce their new chairman and recently named board members representing a diverse coalition of Maryland technology, life sciences, legal and academic professionals.
Incoming Chairman Rene B. LaVigne has over 25 years of sales, marketing, operations, finance and accounting experience in the information technology and financial industries. He also serves as President and Chief Executive of Iron Bow Technologies.
When historians look back at the presidential election of 2016 they will certainly have many questions, but perhaps the biggest one isn’t getting enough attention today. “What the (insert the popular profanity of the future)?” they will likely ask. “Why was there hardly any mention of climate change?” Or will the future inhabitants of Earth be so distracted by survival that they won’t even care what happened in 2016 when the greatest country on the planet at that time denied this problem existed?
Building Specifications:
Relevant Health alumni, Agewell Biometrics is in the running to win the Medstartr Open Crowd Challenge. You can suppoprt them and help end the epidemic of avoidable falls in the elderly. Make a tax deductable donation or show your support by 'Liking' the campaign and help Agewell over the finish line.
Agewell's Equilibrium™ platform is the first automated, fall prevention system. Using a smartphone, and soon a wearable sensor, Equilibrium™ measures strength, balance and physical function in order to identify fall risk, giving an early window of opportunity to take the right preventative steps before a fall happens.
One in three people aged 65 years and older fall every year - the leading cause of injury-related deaths amongst older adults, in addition to causing loss of independence, social isolation and depression. As many as 50% of these falls could be prevented with simple exercises, but only once a problem is identified. Equilibrium™ gives you the early warning for fall risk and soon you'll be able to download it on your iOS or Android phone as a simple-to-use app.
Thursday, December 1, 2016 | 6:00 – 8:30 p.m.
The more than 25 Showcase companies are some of the best from the robust U.S.-Israel Business ecosystem in fields including cyber security, homeland security, bio/pharma, environmental, healthcare, medical device and software. For more information on the companies, go to MarylandIsrael.org/showcase2016.
The mosquito-borne Zika virus — described in recent, grim federal warnings as "not controllable by current technologies"— could become an important source of hope for a regrouped Novavax Inc.
Gaithersburg-based Novavax (NASDAQ: NVAX), still recovering from stunning negative results from its phase 3 trials of its lead respiratory syncytial virus (RSV) vaccine for older adults, said this week that it had "exciting preclinical data" from its new Zika program.
The day following the election of Donald J. Trump as President, a survey of leaders in biotechnology in the United States, conducted by GENETIC ENGINEERING & BIOTECHNOLOGY NEWS (GEN), showed that Trump’s presidency will negatively impact NIH research funding as well as STEM education; a plurality said it will also spark a “brain drain” as foreign-born researchers educated in American universities will be more likely to leave.
A diagnostic test developer, miDIAGNOSTICS, has inked a deal with a Baltimore-based healthcare startup emocha to provide a way to conduct diagnostic tests through silicon chips and transmit those lab test results through the cloud, according to a press release.
The cofounders of startup that is looking to develop a vaccine for HPV are heading to a Buffalo accelerator.
PathoVax is among the new class of startups at 43North. A panel of judges and experts selected them as finalists after a big, fancy pitch competition held in late October meant to showcase Buffalo’s emerging tech chops.
Montgomery County’s Business Innovation Network is pleased to announce that Rockville’s own ReveraGen BioPharma, Inc., a Rockville Innovation Center tenant, granted an option to in-license vamorolone to Swiss company Actelion Ltd. This agreement marks the first tech transfer out of Children’s National Medical Center. Prior to moving to the Rockville Innovation Center, ReveraGen made their home at the Shady Grove Innovation Center.
Actelion Ltd and ReveraGen BioPharma, Inc., announced via press release that they entered into an agreement on November 3, 2016. By this agreement, Actelion has obtained an exclusive option to in-license ReveraGen’s lead compound vamorolone for the treatment of Duchenne Muscular Dystrophy at two different stages in its development.
A new five-year collaboration between Johns Hopkins University and biopharmaceutical company Bristol-Myers Squibb aims to determine why some patients being treated for cancer respond to immunotherapy drugs called checkpoint blockers and some do not, and to develop more effective combination immunotherapies.
Projects included in the collaboration will span laboratory research on patients' tumor samples and several early-stage clinical trials led by Johns Hopkins scientists at the Bloomberg-Kimmel Institute for Cancer Immunotherapy.
Thu, November 17, 20164:30 PM – 8:30 PM EST
Join more than 400 of the region’s business and government leaders for the Economic Alliance of Greater Baltimore’s Annual Meeting, November 17, 2016 at the Baltimore Marriott Waterfront. While Maryland is known for its history and culture, food and beautiful landscape, this year’s annual meeting will celebrate one of the region’s greatest assets – the people – as they tell their stories. The program will recognize the region’s growing companies and those who make our community a world-class market in which to live, work, learn and invest.
miDIAGNOSTICS, global developer of integrated diagnostic solutions for the point-of-need, announces that it has established a collaboration with emocha Mobile Health Inc. from Baltimore, MD, USA. A Johns Hopkins startup company, emocha has developed a platform of digital mobile applications that streamline the continuum of care. The goal of the collaboration is to enable mobile health solutions based on the miniaturized products for point-of-need under development by miDIAGNOSTICS.
Qiagen N.V., a leading global provider of sample to insight solutions, announced the validation of new and improved sequencing chemistry for its GeneReader NGS System, the world’s first complete Sample to Insight solution making the benefits of next-generation sequencing (NGS) accessible to any laboratory.
Qiagen published new, excellent performance data of the Qiagen GeneReader NGS System using the new sequencing chemistry and Qiagen’s GeneRead QIAact Actionable Insights Tumor Panel. Data generated from the GeneReader NGS System with the new chemistry showed 100% concordance with results of Qiagen’s FDA approved therascreen KRAS RGQ PCR assay, the company’s CE-labelled therascreen RAS Extension Pyro Assay as well as with an alternative next-generation sequencing (NGS) sequencer from another vendor. In this study, 42 metastatic colorectal cancer FFPE samples were tested with previously confirmed RAS mutational status.